Diabetes is an important chronic disease which incidence is globally increasing and however considered as an epidemic. This growth in diabetes prevalence, driven principally by an increased prevalence of type 2 diabetes (T2D), is occurring in both developing and developed countries. The incidence of type 1 diabetes (T1D) is also increasing in parallel to that of T2D worldwide. Individuals with diabetes and with chronically poor metabolic control can experience micro vascular and macro vascular complications leading to a significant burden for the individual and for the society. This burden includes direct costs of medical care and indirect costs, such as loss of productivity, which result from diabetes-related morbidity and premature mortality Health care expenses for people with diabetes is more than double of that for people without diabetes; the direct and indirect expenditures attributable to diabetes. The International Diabetes Federation (IDF) estimated that diabetes accounts for 5–10% of the total healthcare budget in many countries.
Cardiovascular diseases are the most prevalent cause of mortality and morbidity among people with T2D and T1D. The presence of cardiovascular diseases and stroke was found in 68% and 16% of deaths related to diabetes among people older than 65 years, respectively. Adult individuals with diabetes present rates of mortality because of heart disease and stroke from two to four times higher than those without diabetes. It has been stated that patients with T2D without a previous history of myocardial infarction have the same risk of coronary artery disease as nondiabetic subjects with a history of myocardial infarction. However, there is still some uncertainty as to whether the cardiovascular risk given by diabetes is truly equivalent to that of a previous myocardial infarction. In general, patients with diabetes aggregate other comorbidities such as obesity, hypertension, and dyslipidemia which also contribute to increasing the risk for cardiovascular diseases. Although there is strong evidence that supports both the efficacy and cost effectiveness of programs directed towards improvement of glycemic control and other cardiovascular risk factors in patients with T2D and T1D, the majority of these patients never achieve the goals established by guidelines issued by diabetes societies.
Contact details:
Alina Grace
Program Manager | Obesity Middle East 2019
Email id: obesityendo@mehealthevents.org
No comments:
Post a Comment